Published Study Demonstrates Natera's Ability to Identify Heterogeneous Cancer Mutations in Patients with Early-Stage Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. ABBV
5. NAVN
6. CNC
7. KFY
8. MU
9. DPZ
10. PLTR

Go back to Published Study Demonstrates Natera's Ability to Identify Heterogeneous Cancer Mutations in Patients with Early-Stage Lung Cancer

Piper Jaffray Cuts Price Target on Natera (NTRA) Following a 4Q Upside

March 9, 2016 7:10 AM EST

Piper Jaffray maintained an Overweight rating on Natera (NASDAQ: NTRA), and cut the price target to $22.00 (from $24.00), following the company's 4Q earnings report. Revenue increased 6% yoy to $52.9M, well above consensus' $45.2M estimates. Adjusted EPS of ($0.31) was $0.33 above Street consensus' ($0.64) estimate.

Analyst William Quirk commented, "Nateras 4Q15... More